Genentech’s PFS Data May Help Inavolisib Compete In PI3KCA-Mutated Breast Cancer

 
• By Joseph Haas
Genetech
Genentech's inavolisib may offer a new treatment option in HR+/HER2- breast cancer • Source: Shutterstock: Michael Vi

More from Clinical Trials

More from R&D